Hospira submits BLA for epoetin alfa biosimilar in USA

January 13, 2015 11:26 AM

Hospira, Inc., announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Retacrit™, a proposed biosimilar to Amgen’s EPOGEN® (epoetin alfa) and Janssen’s PROCRIT ® (epoetin alfa).

The biosimilar application was submitted on Dec. 16, 2014, under the new 351(k) approval pathway created by the Biologics Price Competition and Innovation Act of 2009 (BPCIA).

“As one of the first companies to submit a biosimilar application in the United States, we are proud to be a leader who can help our country’s healthcare system decrease unsustainable costs by embracing a new frontier in medicine,” said Sumant Ramachandra, M.D., Ph.D., senior vice president, chief scientific officer, Hospira. “Hospira is proud to build upon our global experience of providing biosimilars to patients across the world.”

Biosimilars are biologic drugs that are highly similar to a reference biopharmaceutical product and demonstrate no clinically meaningful differences in terms of the safety, purity and potency of the product. Biosimilars offer high-quality, lower-cost alternatives to reference biologics.


Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)

Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?


Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!